The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial

Phil Vinall

doi:10.1177/155989771215006

Phil Vinall

Yale Cancer Center, New Haven, Connecticut, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Daniel P. Petrylak

Yale Cancer Center, New Haven, Connecticut, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Article
Info & Metrics
eLetters
PDF

You are using an old browser, click here to download PDF

PDF Container

PreviousNext

Tools

Download PDF

View Full Page PDF

Citation Tools

The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Thank you for your interest in spreading the word on MD Conference Express.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial

Message Subject (Your Name) has sent you a message from MD Conference Express

Message Body (Your Name) thought you would like to see the MD Conference Express web site.

Your Personal Message

The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial

Permalink: Copy

Linkedin Share Button